Related Experiment Videos

Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells

U Saxena1, E Ferguson, R S Newton

  • 1Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.

Atherosclerosis
|January 6, 1995
PubMed

Insights

Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors reduce monocyte adhesion to endothelial cells, a key factor in atherosclerosis development. This effect is mediated by decreased leukotriene B4 (LTB4) production.

Area of Science:

  • Cardiovascular Biology
  • Atherosclerosis Pathogenesis
  • Endothelial Cell Function

Background:

  • Monocyte adhesion to the aortic endothelium is a critical early event in atherosclerosis.
  • The specific role of endothelial acyl-coenzyme A:cholesterol-acyltransferase (ACAT) in this process remains unclear.
  • Lipopolysaccharide (LPS) is known to increase monocyte adhesion to endothelial cells.

Purpose of the Study:

  • To investigate the role of endothelial ACAT in regulating monocyte adhesion to the aortic endothelium.
  • To determine if ACAT inhibitors can modulate monocyte-endothelial cell interactions.

Main Methods:

  • Utilized specific ACAT inhibitors (CI-976 and PD 132301-2) in porcine aortic endothelial cell cultures.
  • Assessed monocyte (U937 cells) adhesion to endothelial cells stimulated with LPS.
  • Measured endothelial cell ACAT activity and leukotriene B4 (LTB4) synthesis.
  • Investigated the effect of exogenous LTB4 on monocyte adhesion in the presence of ACAT inhibitors.

Main Results:

  • ACAT inhibitors CI-976 and PD 132301-2 significantly reduced LPS-induced monocyte adhesion to endothelial cells.
  • CI-976 treatment decreased both endothelial cell ACAT activity and LTB4 production.
  • The inhibitory effect of CI-976 on monocyte adhesion was reversed by the addition of exogenous LTB4.

Conclusions:

  • Endothelial ACAT activity contributes to monocyte adhesion, likely through modulation of LTB4 synthesis.
  • ACAT inhibitors demonstrate potential as therapeutic agents to reduce monocyte recruitment in atherosclerosis.
  • These findings suggest a novel mechanism underlying the anti-atherosclerotic effects of ACAT inhibitors.

Related Concept Videos